Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies.

HIV Med · 2025 · PMC12127236 · PMID 40116337

Europe PMC DOI

hedged sentence

0.0517

closest p · 1.0× alpha

0.0517

boldest claim

The sentences

did not reach statistical significancep = 0.0517so close (0.05 < p ≤ 0.1)

Proportionally fewer Hispanic/Latine participants had treatment‐emergent hypertension (6% [8/136]) than did non‐Hispanic/Latine participants (12% [49/402]), but this difference did not reach statistical significance ( p = 0.0517).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.